Form 4 for HAE HAEMONETICS CORP
Accepted 2024-05-29 00:00:00 ET · period of report 2024-05-28 · accession 0001127602-24-016810 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-05-29 | 2024-05-29 | HAE | Basil Michelle L | EVP, GC | S - Sale | $88.08 | -13.0K | 35.4K | -27% | -$1.14M |
| 2024-05-29 | 2024-05-28 | HAE | Basil Michelle L | EVP, GC | F - Tax | $95.73 | -11.8K | 44.2K | -21% | -$1.13M | |
| 2024-05-29 | 2024-05-28 | HAE | Basil Michelle L | EVP, GC | A - Grant | $0.00 | +24.7K | 56.0K | +79% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-29 | S | D | 4,094 | $88.57 | 31,257 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.92, inclusive. (F2) This number includes unvested restricted stock units ("RSUs") previously reported. |
| 2 | Common | Common Stock | 2024-05-28 | F | D | 11,758 | $95.73 | 44,247 | D | — | — | (F3) Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. (F2) This number includes unvested restricted stock units ("RSUs") previously reported. |
| 3 | Common | Common Stock | 2024-05-28 | A | A | 24,748 | $0.00 | 56,005 | D | — | — | (F1) Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024. (F2) This number includes unvested restricted stock units ("RSUs") previously reported. |
| 4 | Common | Common Stock | 2024-05-29 | S | D | 8,896 | $87.86 | 35,351 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4. (F2) This number includes unvested restricted stock units ("RSUs") previously reported. |